Abdel Saci

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

Padmanee Sharma, Margitta Retz, Arlene O. Siefker‐Radtke et al. · The Lancet Oncology · 2017 · 1.7K citations

Urology, Metastatic Urothelial Carcinoma, Genitourinary Cancer +6

Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 Trial

Célèste Lebbé, Nicolás Meyer, Laurent Mortier et al. · Journal of Clinical Oncology · 2019 · 384 citations · Full text

Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial

Padmanee Sharma, Russell K. Pachynski, Vivek Narayan et al. · Cancer Cell · 2020 · 371 citations

Urology, Oncology, Nivolumab Plus Ipilimumab +8

GOLPH3 modulates mTOR signalling and rapamycin sensitivity in cancer

Kenneth L. Scott, Omar Kabbarah, Mei‐Chih Liang et al. · Nature · 2009 · 349 citations · Full text

Tumor Biology, Signaling Pathway, Medicine +6

Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab Therapy

Paolo A. Ascierto, Georgina V. Long, Caroline Robert et al. · JAMA Oncology · 2018 · 330 citations · Full text